Questions about this study?
The HopeStage team will email you.
TerminatedNCT01121536
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolarity type I
Medication studyAges 18–65Multiple countries
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Birmingham, United States · Anaheim, United States and 118 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 30, 2010
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 867
- Sponsor
- Cephalon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01121536
- Official title
Show the full official title
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Recruitment & locations
TerminatedBirmingham, United States · Anaheim, United States · Cerritos, United States
117 more locations
- Garden Grove, United States
- Imperial, United States
- Oceanside, United States
- Pico Rivera, United States
- San Diego, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Temecula, United States
- Gainesville, United States
- Jacksonville, United States
- Jacksonville Beach, United States
- Lauderhill, United States
- North Miami, United States
- Tampa, United States
- Atlanta, United States
- Smyrna, United States
- Naperville, United States
- Oakbrook Terrace, United States
- Park Ridge, United States
- Lafayette, United States
- Pikesville, United States
- Watertown, United States
- Flowood, United States
- St Louis, United States
- Mount Laurel, United States
- Albuquerque, United States
- Brooklyn, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Raleigh, United States
- Beachwood, United States
- Canton, United States
- Cincinnati, United States
- Dayton, United States
- Oklahoma City, United States
- Allentown, United States
- Media, United States
- Memphis, United States
- Austin, United States
- DeSoto, United States
- Friendswood, United States
- Houston, United States
- Irving, United States
- Orem, United States
- Salt Lake City, United States
- Richmond, United States
- Bellevue, United States
- Kirkland, United States
- Spokane, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- La Plata, Buenos Aires, Argentina
- Rosario, Argentina
- Brisbane, Australia
- Malvern, Australia
- Rio de Janeiro, Brazil
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Kazanlak, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Kelowna, Canada
- Mississauga, Canada
- Penticton, Canada
- Rijeka, Croatia
- Zagreb, Croatia
- Dole, France
- Nîmes, France
- Achim, Germany
- Dresden, Germany
- Budapest, Hungary
- Nagykálló, Hungary
- Catania, Italy
- Florence, Italy
- Pisa, Italy
- Rome, Italy
- Bialystok, Poland
- Gdansk, Poland
- Kielce, Poland
- Krakow, Poland
- Leszno, Poland
- Skorzewo, Poland
- Szczecin, Poland
- Tuszyn, Poland
- Belgrade, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Bratislava, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Trenčín, Slovakia
- Cape Town, South Africa
- Centurion, South Africa
- Johannesburg, South Africa
- Paarl, South Africa
- Pretoria, South Africa
- Alcoy, Spain
- Coslada (Madrid), Spain
- Vitoria-Gasteiz, Spain
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Luhansk, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- S. Oleksandrivka, Ukraine
- Simferopol, Ukraine
- Vinnytsia, Ukraine
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Cephalon.
Does this study involve medication?
Yes. The study involves medication, including Armodafinil.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.